Yaron Werber
Stock Analyst
(1.98)
# 1,327
Out of 4,648 analysts
39
Total ratings
42.86%
Success rate
-7.81%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Yaron Werber
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RARE Ultragenyx Pharmaceutical | Maintains: Buy | $61 → $73 | $51.06 | +42.97% | 2 | Oct 21, 2024 | |
| EXEL Exelixis | Maintains: Buy | $27 → $34 | $34.29 | -0.85% | 2 | Oct 21, 2024 | |
| ASND Ascendis Pharma | Maintains: Buy | $157 → $160 | $125.77 | +27.22% | 4 | Oct 21, 2024 | |
| BNTX BioNTech SE | Maintains: Hold | $98 → $85 | $108.97 | -22.00% | 3 | Aug 6, 2024 | |
| IONS Ionis Pharmaceuticals | Maintains: Buy | $54 → $59 | $38.44 | +53.49% | 1 | Jul 23, 2024 | |
| LEGN Legend Biotech | Maintains: Buy | $71 → $67 | $43.61 | +53.63% | 2 | Jul 15, 2024 | |
| BGNE BeiGene | Maintains: Buy | $236 → $254 | $207.25 | +22.56% | 5 | May 9, 2024 | |
| STOK Stoke Therapeutics | Upgrades: Buy | n/a | $13.10 | - | 1 | Mar 26, 2024 | |
| JSPR Jasper Therapeutics | Initiates: Outperform | n/a | $22.03 | - | 1 | Mar 18, 2024 | |
| IMRX Immuneering | Downgrades: Market Perform | n/a | $1.86 | - | 2 | Mar 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $4.51 | - | 2 | Jan 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $25.39 | - | 1 | Dec 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $612 → $641 | $588.67 | +8.89% | 3 | Dec 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $2.16 | - | 1 | Oct 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $15 → $25 | $0.33 | +7,582.85% | 1 | Feb 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $27.63 | - | 2 | Nov 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $38 | $22.78 | +66.81% | 1 | May 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $0.46 | - | 3 | Apr 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $1.19 | - | 1 | Nov 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $11.53 | - | 1 | Oct 26, 2021 |
Ultragenyx Pharmaceutical
Oct 21, 2024
Maintains: Buy
Price Target: $61 → $73
Current: $51.06
Upside: +42.97%
Exelixis
Oct 21, 2024
Maintains: Buy
Price Target: $27 → $34
Current: $34.29
Upside: -0.85%
Ascendis Pharma
Oct 21, 2024
Maintains: Buy
Price Target: $157 → $160
Current: $125.77
Upside: +27.22%
BioNTech SE
Aug 6, 2024
Maintains: Hold
Price Target: $98 → $85
Current: $108.97
Upside: -22.00%
Ionis Pharmaceuticals
Jul 23, 2024
Maintains: Buy
Price Target: $54 → $59
Current: $38.44
Upside: +53.49%
Legend Biotech
Jul 15, 2024
Maintains: Buy
Price Target: $71 → $67
Current: $43.61
Upside: +53.63%
BeiGene
May 9, 2024
Maintains: Buy
Price Target: $236 → $254
Current: $207.25
Upside: +22.56%
Stoke Therapeutics
Mar 26, 2024
Upgrades: Buy
Price Target: n/a
Current: $13.10
Upside: -
Jasper Therapeutics
Mar 18, 2024
Initiates: Outperform
Price Target: n/a
Current: $22.03
Upside: -
Immuneering
Mar 15, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $1.86
Upside: -
Jan 31, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $4.51
Upside: -
Dec 20, 2023
Initiates: Outperform
Price Target: n/a
Current: $25.39
Upside: -
Dec 12, 2023
Maintains: Outperform
Price Target: $612 → $641
Current: $588.67
Upside: +8.89%
Oct 19, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $2.16
Upside: -
Feb 28, 2023
Maintains: Market Perform
Price Target: $15 → $25
Current: $0.33
Upside: +7,582.85%
Nov 1, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $27.63
Upside: -
May 2, 2022
Initiates: Market Perform
Price Target: $38
Current: $22.78
Upside: +66.81%
Apr 6, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $0.46
Upside: -
Nov 30, 2021
Initiates: Outperform
Price Target: n/a
Current: $1.19
Upside: -
Oct 26, 2021
Initiates: Outperform
Price Target: n/a
Current: $11.53
Upside: -